INDEX

A
Abbreviations, xxvii–xxxi
“ABCDE” algorithm, 116
Abortions, septic
Brucella and, 162–163
ACAM2000 vaccine, 115, 631–632
ACB. See Acinetobacter baumannii
Acellular vaccines, 235
Acinetobacter baumannii
antibiotic resistance, 328
characterization and identification of source, 327–328
epidemiological consultation, 324–327
generalized perspectives, 322–324
inclusion in ESKAPE pathogens, 322, 328–332
molecular analysis, 327–328
strain collection and sampling, 327
U.S. Military Health System response, 328–332
Acronyms, xxvii–xxxi
Active immunization
alphavirus encephalitides, 498–501
Acute respiratory distress syndrome, 663–664
Adjuvants, vaccines, 831–832
Advanced Trauma Life Support, 110, 116, 117
Advisory Committee on Immunization Practices, 141
Aerobiology
biological aerosol exposure systems, 860–864
clinical applications in the U.S., 857–860
conceptual basis of, 857
dosimetry, 863
exposure chambers, 862
exposure systems, 860–862
generators, 861–862
Henderson apparatus, 861
monitoring and control, 862–863
offensive biological development in the U.S., 857–860
overview, 856–857
parameters impacting aerosol dosimetry, 863–864
sampling, 862
Aerosol dosimetry, 863–864
Afghanistan
Acinetobacter infections, 322, 323, 324–327
Al Qaeda biological warfare program, 15
Q fever outbreak, 307
ricin as biological weapon research, 376
Aflatoxins, 443, 445
Africa
Chikungunya outbreak, 674
Ebola virus epidemic, 677–678
African milk bush, 79
Agency for Healthcare Research and Quality, 329
Agent Orange, 79
Agent X, 338
Agglutination tests, 165
Agricultural terrorism, 78–80
Air Force field laboratories, 706
Al Qaeda
biological warfare program, 15, 16–17
Alcide EXSPORE, 883
Alibek, Dr. Kenneth, 254, 339
Alibekov, Colonel Kanatjan, 254, 339
Alphavirus encephalitides
active immunization, 498–501
antigenicity, 483–486
Aum Shinrikyo cult attacks, 13, 46–47
bioterrorism attacks, 13–15
characteristics of organism, 131–132
clinical disease, 135–138
cutaneous, 135–136
diagnosis of, 138–139
epidemiology of, 132
foodborne, 72
gastrointestinal, 138, 650
historical perspectives, 130–131
incidence in the US, 132
inhalational, 136–137
medical countermeasures, 752, 754, 757–761
meningitis, 137
opharyngeal, 138
pathogenesis, 132–135
prophylactic treatment after exposure, 140, 760–761
Radioactive exposure, 417–418
Russian epidemic, 9
vaccines, 10, 113, 114, 753–758
WHO surveillance and control guidelines, 140
Anthrolysin O, 135
Antibacterial monoclonal antibodies, 837–839
Antibiotic resistance diseases, 655–656
Antibiotic susceptibility testing, 729
Antibiotics
Animal Efficacy Rule, 272
anthrax treatment, 139–140
bacterial disease treatment, 759–760
brucellosis treatment, 166–167, 768–769
Clostridium perfringens treatment, 363
glanders treatment, 202–204, 766–767
melioidosis treatment, 233, 766–767
multidrug-resistant bacterial infections, 328
plague treatment, 272, 765
Q fever, 771–772
tularemia treatment, 292–294, 763–764
Antibodies
antibacterial monoclonal antibodies, 837–839
antibody generations, 832–835
antitoxin monoclonal antibodies
Antiviral monoclonal antibodies, 839–842
Antitoxins
C. botulinum pre- and postexposure prophylaxis, 347
for C. tetani, 343–346
for Clostridium perfringens, 363
Antivenoms, 432
Antiviral agents
hemorrhagic fever-causing mammarennaviruses, 531–532
smallpox, 787–788
viral hemorrhagic fevers, 790–791
Antiviral monoclonal antibodies, 839–842
Aquariums
palytoxin exposure, 471–472
Avian influenza A virus, 19–22, 657–660
Avian influenza H5N1 virus, 662–663
Avian influenza H7N9 virus, 663–664
Azithromycin
glanders treatment, 204
Bacillus anthracis
accidental release of, 49–50, 130
active immunization, 140–142
attacks by Germany in 1915–1916, 43–44
attacks in US, 2001, 47–48
Aum Shinrikyo cult attacks, 13, 46–47
bioterrorism attacks, 13–15
characteristics of organism, 131–132
diagnosis of, 138–139
epidemiology of, 132
foodborne, 72
gastrointestinal, 138, 650
historical perspectives, 130–131
incidence in the US, 132
inhalational, 136–137
medical countermeasures, 752, 754, 757–761
meningitis, 137
opharyngeal, 138
pathogenesis, 132–135
prophylactic treatment after exposure, 140, 760–761
Radioactive exposure, 417–418
Russian epidemic, 9
vaccines, 10, 113, 114, 753–758
WHO surveillance and control guidelines, 140
Anthrolysin O, 135
Antibacterial monoclonal antibodies, 837–839
Antibiotic resistance diseases, 655–656
Antibiotic susceptibility testing, 729
Antibiotics
Animal Efficacy Rule, 272
anthrax treatment, 139–140
bacterial disease treatment, 759–760
brucellosis treatment, 166–167, 768–769
Clostridium perfringens treatment, 363
glanders treatment, 202–204, 766–767
melioidosis treatment, 233, 766–767
multidrug-resistant bacterial infections, 328
plague treatment, 272, 765
Q fever, 771–772
tularemia treatment, 292–294, 763–764
Antibodies
antibacterial monoclonal antibodies, 837–839
antibody generations, 832–835
antitoxin monoclonal antibodies
Antitoxins
C. botulinum pre- and postexposure prophylaxis, 347
for C. tetani, 343–346
for Clostridium perfringens, 363
Antivenoms, 432
Antiviral agents
hemorrhagic fever-causing mammarennaviruses, 531–532
smallpox, 787–788
viral hemorrhagic fevers, 790–791
Antiviral monoclonal antibodies, 839–842
Aquariums
palytoxin exposure, 471–472
Avian influenza A virus, 19–22, 657–660
Avian influenza H5N1 virus, 662–663
Avian influenza H7N9 virus, 663–664
Azithromycin
glanders treatment, 204
Bacillus anthracis
accidental release of, 49–50, 130
active immunization, 140–142
attacks by Germany in 1915–1916, 43–44
attacks in US, 2001, 47–48
Aum Shinrikyo cult attacks, 13, 46–47
bioterrorism attacks, 13–15
characteristics of organism, 131–132
diagnosis of, 138–139
epidemiology of, 132
foodborne, 72
gastrointestinal, 138, 650
historical perspectives, 130–131
incidence in the US, 132
inhalational, 136–137
medical countermeasures, 752, 754, 757–761
meningitis, 137
opharyngeal, 138
pathogenesis, 132–135
prophylactic treatment after exposure, 140, 760–761
Radioactive exposure, 417–418
Russian epidemic, 9
vaccine side effects, 142
treatment of, 139–140
vaccines, 10, 113, 114, 753–758
WHO surveillance and control guidelines, 140
Anthrolysin O, 135
Antibacterial monoclonal antibodies, 837–839
Antibiotic resistance diseases, 655–656
Antibiotic susceptibility testing, 729
Antibiotics
Animal Efficacy Rule, 272
anthrax treatment, 139–140
bacterial disease treatment, 759–760
brucellosis treatment, 166–167, 768–769
Clostridium perfringens treatment, 363
glanders treatment, 202–204, 766–767
melioidosis treatment, 233, 766–767
multidrug-resistant bacterial infections, 328
plague treatment, 272, 765
Q fever, 771–772
tularemia treatment, 292–294, 763–764
Antibodies
antibacterial monoclonal antibodies, 837–839
antibody generations, 832–835
antitoxin monoclonal antibodies
Antitoxins
C. botulinum pre- and postexposure prophylaxis, 347
for C. tetani, 343–346
for Clostridium perfringens, 363
Antivenoms, 432
Antiviral agents
hemorrhagic fever-causing mammarennaviruses, 531–532
smallpox, 787–788
viral hemorrhagic fevers, 790–791
Antiviral monoclonal antibodies, 839–842
Aquariums
palytoxin exposure, 471–472
Avian influenza A virus, 19–22, 657–660
Avian influenza H5N1 virus, 662–663
Avian influenza H7N9 virus, 663–664
Azithromycin
glanders treatment, 204
Bacillus anthracis
accidental release of, 49–50, 130
active immunization, 140–142
attacks by Germany in 1915–1916, 43–44
attacks in US, 2001, 47–48
Aum Shinrikyo cult attacks, 13, 46–47
bioterrorism attacks, 13–15
characteristics of organism, 131–132
diagnosis of, 138–139
epidemiology of, 132
foodborne, 72
gastrointestinal anthrax, 138, 650
historical perspectives, 130–131
incidental anthrax, 136–137
Bacillus anthracis
accidental release of, 49–50, 130
active immunization, 140–142
attacks by Germany in 1915–1916, 43–44
attacks in US, 2001, 47–48
Aum Shinrikyo cult attacks, 13, 46–47
bioterrorism attacks, 13–15
characteristics of organism, 131–132
diagnosis of, 138–139
epidemiology of, 132
foodborne, 72
gastrointestinal anthrax, 138, 650
historical perspectives, 130–131
incidental anthrax, 136–137

Index
Medical Aspects of Biological Warfare

medical countermeasures, 752, 754, 757–761
meningitis, 137
opharyngeal anthrax, 138
pathogenesis, 132–135
prophylactic treatment after exposure, 140, 760–761
Russian anthrax epidemic and, 9
treatment of, 139–140
vaccine for US military, 10
vaccines, 10, 113, 114, 753–758

Bacillus cereus, 132, 134
Bacillus welchii, 362

Bacterial culture techniques
glanders, 198–199
tularemia, 293

Bacteriophages, 202

Baghdad, Iraq
Acinetobacter infections, 325–326, 328
BALB/c mice, 186, 188, 205

Balkengrippe. See Q fever
Bangladesh
Nipah virus outbreak, 553–554, 670

BAT, 345
Bats
influenza viruses in, 664–666

BCA agar, 199
BCX4430, 791
Bedbugs
as plague vector, 256–257

Bee venom, 420, 421
Belladonna, 449
Belladonna toxicity
differentiating from botulism, 343
Bergendorff, Roger, 16
Beta-bungarotoxin, 367
Biochemical identification, 199
Biocrimes, 12
Biodefense and Pandemic Vaccine and Drug Development Act Renewal of 2011, 933
Biofire Defense FilmArray, 702
Biological aerosol exposure systems, 860–864
Biological agents. See also specific agents by name
accidental release of, 49–50
biocrimes, 12
biological surety, 898–910
biosafety, 904–905
biosurety, 908–910
centralized management of, 900–901
critical agents for health preparedness, 113
delivery systems developed by Iraq, 11
disarmament, 17–18
dual use research of concern, 19–22
duplicate culture, 18
early use of, 2–3
ehospital infection control precautions, 121
the Iranian program, 12
the Iraqi program, 10–11
the Libyan program, 12
the North Korean program, 12
pan-hazard preparedness, 17–24
produced by the US military, 5
prophylaxis against diseases caused by Category A agents, 119
regulated biological select agents and toxins, 703
risk assessment systems, 95
the South African program, 11–12
the Soviet program, 8–10
study of natural outbreaks for potential bioweapon use, 50–54
the Syrian program, 12
therapy of diseases caused by Category A agents, 119

the US program, 4–8
use during the World Wars, 3–4
Biological and Toxin Weapons Convention, 375
Biological Defense Research Program Laboratories, 888
Biological Incident Annex, 94, 98
Biological Integrated Detection System, 112
Biological Personnel Reliability Program, 898, 901, 905–908
Biological safety. See Biosafety
Biological safety cabinets, 860
Biological select agents and toxins
biosafety, 904–905
biosecurity, 908–910
centralized management of, 901
control of, 898–899
identifying, 904
incident response and emergency management, 910–911
inventory and accountability, 900–901
inventory audits, 901–902
inventory discrepancies, 911
list of Tier 1 agents and toxins, 898
permisssible toxin amounts, 903
personnel reliability, 905–908
registration for possession, use, and transfer of, 899
reporting theft, loss, or release of, 903–904
restricted experiments, 904
sample criteria for retaining or destroying, 901
security breaches, 911
security risk assessment, 900
theft, loss or release of, 910
transfers, 902–903

Biological select agent and toxin transfers, 902–903
biological select agents and toxins inventory and accountability, 900–901
biological select agents and toxins inventory audits, 901–902
biosafety, 904–905
biosecurity, 908–910
centralized management of long-term biological select agents and toxins, 901
centralized management of long-term biological select agents and toxins, 901
control of biological select agents and toxins, 898–899
identifying select agents and toxins, 904
incident response and emergency management, 910–911
information security, 909–910
international rules and treaties to limit or ban biological weapons use, 896
inventory discrepancies, 911
operational security, 909
overview, 897–898
personnel reliability, 905–908
personnel security, 909
physical security, 909
registration for possession, use, and transfer of biological select agents and toxins, 899
reporting theft, loss, or release of biological select agents and toxins, 903–904
restricted experiments, 904
security breaches, 911
security risk assessment, 900
theft, loss or release, 910

Biological Surety Program, 888
Biological terrorism. See Bioterrorism
Biological warfare
impact of advanced molecular techniques on epidemiology of, 58–59

Biological Weapons Convention, 8, 11, 17–18, 179, 338, 375, 897
Biologics Control Act, 926
Biomarkers, 716–718
Index

Botulinum toxin
- antitoxins, 345–346
- bioterrorist attack signs, 346–347
- botulinum neurotoxin production, 340–341
- clinical disease, 341–342
- description of agent, 72–73, 340–341
- diagnosis of, 343–344
- diagnostic assays, 343–344
- foodborne botulism, 72–73, 342, 344
- historical perspectives, 338–340
- inhalation-acquired botulism, 342, 344
- pathogenesis, 341
- prophylactic treatment, 347, 794–795
- symptoms of, 342
- therapeutic drug research, 348–349
- treatment of, 343–349
- vaccine research, 348, 793–794

BPFRP. See Biological Personnel Reliability Program

Brazilian hemorrhagic fever, 521

Brevetoxins, 463, 465–467

Brooke Army Medical Center
- Acinetobacter infections, 324

Brucella
- host specificity, 161
- lipopolysaccharide epitopes, 161–162
- nomenspecies, 160–161
- virulence factors, 162
- Brucella abortus, 163
- Brucella canis, 162
- Brucella melitensis, 164
- Brucella suis development as biological weapon, 160

Brucellosis
- clinical manifestations, 164–165
- diagnosis of, 165–166
- epidemiology of, 162
- historical perspectives, 160
- infectious agent characteristics, 160–162
- medical countermeasures, 768–770
- minimum inhibitory concentration breakpoint ranges, 167
- pathogenesis, 163
- prophylactic treatment, 167, 769–770
- symptoms and signs of, 164
- treatment of, 166–167
- vaccines, 768

BSAT. See Biological select agents and toxins

Bubonic plague, 265, 267

Buffalopox, 623, 628

Bundibugyo virus, 571–573, 589, 592

BurkDD, 200

Burkholderia mallei
- animal disease models, 186–189
- attacks by Germany in 1915-1916, 43–44, 78
- biochemical identification, 199
- characteristics of, 181–182
- clinical disease in animals, 191–193
- clinical disease in humans, 193–198
- clinical features of laboratory-acquired infections, 196–197
- control of, 208–109
- decontamination, 208–109
- diagnosis in equines, 202
- differentiation from B. pseudomallei, 181, 182
- epidemiology of, 182–183
- growth characteristics, 198
- historical perspectives, 179–181
- host immunity, 205–206

xxxiii
Medical Aspects of Biological Warfare

identification of, 199–201
immunological detection, 201
immunotherapies, 208
intracellular characteristics, 186
isolation of organism, 198–199
laboratory diagnosis, 198–202
medical countermeasures, 766–768
military relevance, 178–179
morphology, 198
nucleic acid-based identification, 199–201
pathogenesis, 184–191
prophylactic treatment, 205–209, 767–768
septicemia, 195
serologic diagnosis, 201–202
treatment of, 202–204
virulence mechanisms, 189–191

Burkholderia pseudomallei
candidate virulence factors, 228–230
characteristics of, 224–225
clinical disease, 227, 230–232
diagnosis of, 232–233
differentiation from B. mallei, 181, 182
epidemiology of, 226
pathogenesis, 226–227
prevention of, 234–236
treatment of, 233–234

Burnet, Dr. Frank Macfarlane, 306
Bush, George H., 10
Bush, George W., 22, 114

BWC. See Biological Weapons Convention

Byetta, 417

C

Caffa
plague pandemic, 250, 252
CAFOs. See Concentrated animal feeding operations
California
plague pandemic, 251
Camelidae

Camp Detrick, Maryland
biological warfare agents research, 857–858, 923–925
Burkholderia mallei infections, 178, 183, 194–195, 196–197
Campylobacter jejuni, 73, 77, 650–651
Canada
alphavirus encephalitides outbreaks, 482
Capsular polysaccharides, 235
Captopril, 417
Cardiotoxic plants, 448–449
Cardiotoxins, 440–441, 448
Cardiovascular system
Staphylococcal enterotoxin B effects, 407–408
Caribbean Islands
Chikungunya outbreak, 674
Castor beans, 375, 377, 382, 446
Casualty management
alerting authorities, 118–123
chemical protection, 113
diagnosis of casualties, 118, 120
disinfesting or decontaminating, 116–117
epidemiological investigation, 123–124
establishing diagnosis, 117–118
immunologic protection, 113–116
infection control, 118, 121
maintaining level of proficiency, 124
maintaining level of suspicion, 110–112
managing psychological aftermath, 123–124
physical protection, 112–113
primary assessment, 116
prophylaxis against diseases caused by Category A agents, 119
protecting self, 112–116
providing therapy, 118
psychological effects of biological attacks, 123–124
saving patient’s life, 116
secondary assessment, 116–118
therapy of diseases caused by Category A agents, 119
Catalytic A-chain, 377–378, 380, 390
Cationic liposome DNA complexes, 208
Cats
plague transmission role, 257
Centipedes, 443
Central America
alphavirus encephalitides outbreaks, 482, 487–488
Chikungunya outbreak, 674
Central Intelligence Agency, 8, 377
CFT. See Cell-free translation assay; Complement fixation test
Chapare virus, 673
Chemical Battalions, 117
Chemical-Biological Incident Response Force, 117, 123
Chemical Corps, 116
Chemical nerve agent poisoning
differentiating from botulism, 343
Chemical protection, 113
Chemical Warfare Service, 5
Chemical Weapons Convention, 375
CHEMPACKs, 102
Chikungunya, 673–674
China
accusations of US biowarfare attacks, 6–7
Avian influenza H7N9 virus infections, 663–664
plague pandemic, 251
severe fever with thrombocytopenia syndrome virus, 673–676
Index

Chloramphenicol
  glanders treatment, 204
  melioidosis treatment, 234
  plague treatment, 272
Chloroform:methanol residue vaccine, 312
Chloroquine
  Q fever treatment, 311
Cholera, 647–649
Cidofovir, 635
Ciguatoxic fish, 422, 462
Cilastatin
  melioidosis treatment, 234
Ciprofloxacin
  anthrax exposure prophylaxis, 10, 140
  anthrax treatment, 139
  plague treatment, 272
Civil Support Teams, 123
Clavulanate
  glanders treatment, 204
  melioidosis prophylaxis, 236
CLIA. See Clinical Laboratory Improvement Amendments
Clindamycin
  anthrax treatment, 140
Clorox Ultra Germicidal Bleach, 883
Clostridium argentinense, 340
Clostridium baratii, 340
Clostridium botulinum
  antitoxins, 345–346
  bioterrorist attack signs, 346–347
  botulinum neurotoxin production, 340–341
  clinical disease, 341–342
  description of agent, 72–73
  diagnosis of, 343–344
  diagnostic assays, 343–344
  foodborne botulism, 72–73, 342, 344, 651
  historical perspectives, 338–340
  inhalation-acquired botulism, 342, 344
  pathogenesis, 341
  prophylactic treatment, 347
  symptoms of, 342
  therapeutic drug research, 348–349
  treatment of, 345–349
  vaccine research, 348
Clostridium butyricum, 340
Clostridium perfringens
  alpha toxin, 362–363
  chemical properties, 364
  description of, 363–365
  diseases, 363
  historical perspectives, 362–363
  mechanism of action, 364–365
  medical management, 366–367
  natural occurrence of, 363–364
  physical properties, 364
  signs and symptoms of, 365–366
  toxin types, 362
Clostridium perfringens type D, 365–366
Clostridium welchii, 362
Cnidarians, 420–422
Co-trimoxazole, 203
Colony collapse disorder, 678
Colorado potato beetle, 79
Common source outbreaks, 40
Community Emergency Response Team Program, 100
Competent medical authority, 907
Complement fixation test, 201, 202
Comprehensive Health Surveillance, 739
Comprehensive Preparedness Guide 201, 95
Concentrated animal feeding operations, 79
Confirmation identification methods, 709–716
Congo
  incidence of human plague cases, 259
Congressional Office Building
crin bioterrorism attack, 16
Consequence management
  Comprehensive Preparedness Guide 201, 95
  consequences of biological incidents, 96–98
  definition of, 94
  local and national response, 98–102
  National Disaster Recovery Framework, 94
  recovery, 103–105
  risk assessment systems, 95
Convention on the Prohibition of the Development, Production
and Stockpiling of Bacteriological and Toxin Weapons and on
their Destruction, 8, 11, 17–18, 179, 338, 375
Cooperative Biological Engagement Program, 10
Corals
  palytoxin exposure, 469, 471–472
Coronaviruses, 666–669
Countermeasures. See Medical countermeasures
Cowpox, 623, 628
Coxiella burnetti
  characteristics of, 307–309
  diagnosis of, 311
  disease in animals, 310
  disease in humans, 310
  epidemiology of, 309–310
  historical perspectives, 306
  medical countermeasures, 770–772
  military relevance, 306–307
  pathogenesis, 309
  postexposure prophylaxis, 772
  treatment of, 311
  vaccines, 312, 770–771
Coxielliosis, 310
Critical control points, 81
Crocus, 447
Crooker, Michael, 16
Crop diseases, 79
Cruikshank, George, 918
Cryptosporidiosis, 75
Cryptosporidium parvum, 75, 77, 78
Culture-based methods, 722–724, 727–728
Cutaneous anthrax, 135–136
Cutaneous plaque, 268–269
Cyanogenic plants, 448
Cysticercosis, 77
Cytotoxic plants, 446–447
Czechoslovakia
  use of biological agents during World War II, 4
Dalles, Oregon
Salmonella typhimurium attacks, 1984, 44–46
Darwin Prospective Melioidosis Study, 227, 230, 234
Daschle, Tom
  anthrax attack, 2001, 47–48
Decontamination
  glanders, 208–109
  Decontamination procedures, 104, 116–117
Definition of biological warfare, 7
Defense, 7
Defense Science and Technology Laboratory, 388
Defence Laboratory Network, 706–707
Delaware

dangue fever outbreaks, 482
Dengue fever, 671–672
Department of Defense Global Emerging Infections Surveillance and Response System, 324, 329, 331
Dermal exposure
palytoxin, 471
Derrick, Dr. Edward Holbrook, 306
Despeciated equine heptavalent antitoxin, 345
DHHS. See U.S. Department of Health and Human Services
DHS. See U.S. Department of Homeland Security
Diagnostic tests, in vivo/in vitro, 728
Digital imaging, 202
Dilger, Anton, 44, 78, 178
Diphtheria
differentiating from botulism, 343
Disinfection procedures, 116–117
Division of Select Agent and Toxins, 860, 897–898
DNA assays, 199–201
DNA vaccines, 500
DoD-Geis. See Department of Defense Global Emerging Infections Surveillance and Response System
Dominant-negative inhibitors, 366
Dominican Republic
colera outbreak, 648
Domoic acid, 463, 467–469
Dosimetry, 863
Doxycycline
anthrax exposure prophylaxis, 140
anthrax treatment, 139
brucellosis treatment, 166–167
glanders treatment, 203–204
meliodosis treatment, 234
plague postexposure prophylaxis, 273
plague treatment, 272
Q fever treatment, 311
Drug-resistant bacteria. See Multidrug-resistant organisms
Dryvax, 631–632
Dual use research of concern, 19–20
DURC. See Dual use research of concern
Dutschke, Everett, 16, 377
Dysentery, 363
Eastern equine encephalitis, 484–485, 493–494
Ebola virus, 118, 571, 573–575, 580–592, 596–598, 677–678
ECL. See Electrochemiluminescence
Eczema vaccinatum, 633
Edema toxin, 132–135
Ehrlich, Paul, 375
Ehrlichiosis, 654–655
“Eight Ball,” 859, 925
Electrochemiluminescence, 385, 386, 387, 730–732
Electronic Surveillance System for the Early Notification of Community-based Epidemics, 57
ELISA. See Enzyme-linked immunosorbent assays
Emergency management, 910–911
Emergency Operations Center, 345
Emergency support functions, 98, 101, 123
Emergency Use Authorization, 703, 740–741, 925–926, 929
Emerging infectious diseases
antibiotic resistance, 655–656
avian influenza, 657–660
bacterial diseases, 647–657
chikungunya, 673–674
coronaviruses, 666–669
definition of, 646
Dengue fever, 671–672
Ebola epidemic in West Africa, 677–678
factors contributing to, 646
foodborne diseases, 650–652
generically engineered organisms, 679–681
genomic epidemiology, 656–657
high-throughput DNA sequencing, 678–679
H1N1 influenza pandemic, 660–661
human infection with avian influenza viruses, 661–664
influenza viruses in bats, 664–666
mosquitoborne viruses, 670–674
paramyxoviruses, 669–670
swine influenza, 660–661
synthetic biology, 681
tickborne diseases, 652–655
tickborne phleboviruses, 675–677
viral diseases, 657–679
waterborne diseases, 647–650
West Nile virus, 672–673
Encephalitis. See Alphavirus encephalitides
Encephalomyelitis
nonviral causes of, 496
viral causes of, 495
Endocarditis, Q fever, 310
Endo pep-MS, 344
England
plague pandemic, 250
Enhanced Response Force Package Teams, 123
Enrofloxacin
glanders treatment, 204
Enterohemorrhagic E. Coli, 74
Enterotoxemia, 363, 365
Envenomation, 417, 418
Environmental niche modeling, 583
Environmental Protection Agency, 101
Enzootic
definition of, 249
Enzyme-linked immunosorbent assays
botulism diagnosis, 344
brucellosis diagnosis, 165, 166
filoviruses diagnosis, 593–595
glanders diagnosis, 201, 202
hemorrhagic fever-causing mammarenaviruses diagnosis, 529–530
orthopoxviruses diagnosis, 629
overview, 728–730
plague diagnosis, 270
Q fever diagnosis, 311
ricin diagnosis, 385, 387
Staphylococcal enterotoxin B diagnosis, 408
EpiCenter application, 57
EPICON. See Epidemiological consultations
Epidemics
clues to an unnatural event, 39–41
definition of, 38
downwind plume patterns, 41
Ebola virus in West Africa, 38
epidemic waves, 42
multiple epidemics, 40
outbreak investigation, 41–43
recognition of, 38–39
Epidemiological consultations, 324–327
Epidemiology
accidental release of biological agents, 49–50
assessment tool, 54–56
xxxvi
bioterrorism events, 43–49
clues to an unnatural event, 39–41, 111
common source outbreaks, 40
of epidemics, 38–43
the epidemiological triangle, 38
impact of advanced molecular techniques, 58–59
improving recognition and surveillance of bioterrorism, 56–58
investigations after biological attacks, 123–124
point source outbreaks, 40
study of natural outbreaks for potential bioweapon use, 50–54
Epizootic
definition of, 249
Epsilon toxin vaccine, 567
Equine encephalitis. See Alphavirus encephalitides
Equines
C. botulinum antitoxin, 347
glanders diagnosis, 202
Escherichia coli, 74, 77, 78, 377, 651–652
Escherichia coli O104:H4, 652
Escherichia coli O157:H7, 651–652
ESKAPE pathogens, 322, 328–332
Ethical issues
Animal Efficacy Rule, 931–932
biodefense, ethics, and research in the 20th Century, 921–925
biodefense and ethics in the 18th and 19th Centuries, 918–921
Biodeterrence and Pandemic Vaccine and Drug Development Act Renewal of 2011, 933
BioShield Act of 2004, 932–933
conflict between regulations and ethical responsibilities, 926–929
current movements in the regulatory environment, 931–933
dilemmas for biodefense research, 933–934
DoD/FDA Memorandum of Understanding, 927
impact of regulating agencies on strategic research, 925–926
investigational new drug status, 927–929
options for fulfilling mission and ethical responsibilities to military personnel, 929–931
overview of, 916–925
Public Health Security and Bioterrorism Preparedness and Response Act of 2002, 931
summary points, 929
The Turner Bill, 933
EUA. See Emergency Use Authorization
Europe
plague pandemic, 250–251
Excitatory neurotoxins, 430–432
Exendin-4, 417
Expeditionary Medical Dental Group, 326
Exposure chambers, 862
Exposure systems, 860–862
Eyes
Staphylococcal enterotoxin B effects, 408
F
F1 antigen, 262
F1-V vaccine, 273–274
Fairchild Air Force Base
ricin attacks in 2004, 377
Farcy. See Glanders
Favipiravir, 791
FBI. See Federal Bureau of Investigation
Federal Bureau of Investigation, 14, 45, 101
Federal Emergency Management Agency, 94, 100
Federal Experts Security Advisory Panel, 23
Federal Response Plan, 22
Federal Select Agent Program, 20, 897–900, 904–906
FEMA. See Federal Emergency Management Agency
Field laboratories, military, 705–706
FilmArray, 738
Filoviruses
behavioral modification for prevention, 586
categorization of viruses, 571–572
clinical presentation of disease, 590–591
decontamination, 586
diagnosis of, 591–595
disease nomenclature, 571, 574
environmental niche modeling, 583
epidemiology of, 580–583
epizootiology of, 580
filovirion structure, 572
function of, 576–579
genomes, 572–573, 575
geographic distribution, 574
inactivation of, 586
lifecycle, 573–574
molecular biology, 572–583
natural reservoirs of, 574–575
nomenclature, 571–572
pathogenesis, 587, 590
prevention of, 586–587
proteins, 572–573
serological surveys, 583
Soviet biological warfare program, 584–586
taxonomy, 571
transmission of, 583–584
treatment of, 595, 596–598
vaccines, 587, 588–589
Fimbriae, 262–263
Fish, venomous, 420–422
Fleas
as plague vector, 256–257
plague virulence and transmission factors, 264
Florida
plague pandemic, 251
Flow cytometry, 732–733
Flu Near You, 57
Fluorescence in situ hybridization assay, 202
Fluorescence Resonance Energy Transfer, 630
Fluorescence spectroscopy, 202
Fluorescent antibody staining, 166, 270–271
Food, Drug, and Cosmetic Act, 926
Food and Drug Administration, 82, 112, 272, 587, 702–704, 916, 926–933
Food Emergency Response Network, 101
Food Safety and Modernization Act, 82
Food supply security, 80–82
Foodborne diseases
anthrax, 72
botulinum toxins, 72–73, 342, 344
Campylobacter jejuni, 73, 77, 650–651
Clostridium botulinum, 72–73, 342, 344, 651
Clostridium perfringens diseases, 363
cryptosporidiosis, 75
evergrowing diseases, 650–652
Escherichia coli, 74, 651–652
gastrointestinal anthrax, 650
hepatitis A, 75
listeriosis, 73–74
mycotoxicosis, 75–76
parasites, 76–77
salmonellosis, 44–46, 73, 652
shigellosis, 47, 74–75
threat potential, 76, 77
Foot and mouth disease, 78–79

xxxvii
Medical Aspects of Biological Warfare

Force health protection, 928–929
Fort Detrick, Maryland
Burkholderia mallei infections, 178, 183, 194–195, 196–197
Fox squirrels plaque transmission role, 257
Foxglove, 447
Francisella
Freeman, Dr. Mavis, 306

G

H
Hematology
Staphylococcal enterotoxin B, 408
Hemolytic toxins, 437–440
Hemorrhagic fever-causing mammarenaviruses
antiviral agents, 531–532
clinical presentation, 522–523
cogulopathies, 527–528
diagnosis of, 529–530
epidemiology of, 519–521
historical perspectives, 519–521
immune response, 528–529
molecular characteristics, 524–525
New World mammarenaviruses, 520–521, 523, 526–527, 528–529
Old World mammarenaviruses, 519–520, 522–523, 525–526, 528
passive antibody therapy, 530
pathogenesis, 525–527
pathology, 525–527
phylogenetic relationships, 523–524
reservoirs of, 521–522
taxonomy, 523–524
treatment of, 530–532
vaccines, 530–532
Hemorrhagic toxins, 437–440
Hemostasis-active toxins, 435–437
Hemostasis system, 438–439
Henderson apparatus, 861
Hendra virus, 549, 552–553, 669
Henipaviruses
anti-henipavirus immune response detection, 558–559
antigen detection, 558
availability of, 557–558
as biological weapons, 557–558
clinical presentation, 554–555
diagnosis of, 558–559
dissemination of, 558
emergence of, 549–552
epidemiology of, 552–554
epizootiology of, 552–554
Hendra virus, 549, 552–553
historical perspectives, 549–552
innate immunotherapy, 560
isolation of virus, 559
medical management, 559–560
molecular biology of, 555–556
newly identified viruses, 552
next-generation sequencing, 559
Nipah virus, 549–552, 553–554
passive immunotherapy, 559–560
pathogenesis, 557
pathology, 555
potential for high morbidity and lethality, 558
production of, 558
reverse transcription-polymerase chain reaction, 558
ribavirin, 560
signs and symptoms of, 554–555
therapies evaluated in vitro, 560
virus genome, 555
virus proteins, 555–556
virus structure, 555
Hepatitis A, 75, 77
Hepatitis A virus cellular receptor 1, 367
Herbal medicine
ricin poisoning, 381
Hfab-BAT, 346
HHA. See Handheld assay devices
High-efficiency particulate air filters, 871, 877, 882
High throughput DNA sequencing, 678–679
High throughput screening, 390, 391
Highly pathogenic avian influenza A virus, 19–22, 662–663
H1N1 influenza A virus, 19, 22, 660–661
HSN1 virus, 19–22
Homeland Security Council, 22
Homolatilemers, 365
Hong Kong, China
Avian influenza HSN1 virus infections, 662–663
Horses
glanders diagnosis, 202
Host immunity, 205–206
Host response, 741–743
HTS. See High throughput screening
Human fleas
as plague vector, 256
Hussein, Saddam, 10–11
Hybridization probes, 630
Hydroxychloroquine
Q fever treatment, 311
Iatrogenic botulism, 342, 344
IHA. See Indirect hemagglutination assay
Ilimaquinone, 391
Illumina MiSeq instrument, 740
Imipenem
glanders treatment, 204
melioidosis treatment, 233
Immunization. See also Vaccines
alphavirus encephalitides
anthrax, 140–142
Immunodiagnostic methods, 728–730
Immunologic protection, 113–116
Immunological detection, 201
Immunosorbent assays. See Enzyme-linked immunosorbent assays
Immunotherapies
glanders, 208
IMP dehydrogenase inhibitors, 792
In vivo/in vitro diagnostic tests, 728
Inactivated vaccines, 499
Incapacitating agents
produced by the US military, 5
Incident Command System, 121
Incident response and emergency management, 910–911
IND. See Investigational new drugs
India
Chikungunya outbreak, 674
Nipah virus outbreak, 553–554
plague pandemic, 251
Indian Ocean islands
Chikungunya outbreak, 674
Indian Plague Commission, 256
Indirect hemagglutination assay, 201
Indirect immunofluorescence assay, 311
Infants
botulism, 342, 346
Infection control, 118, 121
Infectious Diseases Society of America, 322
Influenza
Avian influenza pandemic threat, 657–660
H1N1 influenza pandemic, 660–661
Swine influenza, 660–661
Medical Aspects of Biological Warfare

Inhalation-acquired disease
- amnesic shellfish poisoning, 468
- anthrax, 136–137
- botulism, 342, 344
- neurotoxic shellfish poisoning, 466
- palytoxin, 471
- paralytic shellfish poisoning, 464
- ricin, 382–384

Injections
- ricin administration, 382

Innate immunotherapy
- henipaviruses, 560

Insect stings, 420, 421

Institutional Biosafety Committee, 904

Integrated Consortium of Laboratory Networks, 706–707

Intercellular adhesion molecule-1, 406

Interferon gamma, 163, 205–206, 406

Interferons, 791

International Clonal Complex, 323

International Committee of the Red Cross, 6

International Health Regulations, 259

International Society on Toxinology, 416

Invasive species, 80

Inventory audits, 901–902

Invertebrates
- as disease models, 188–189

Investigational new drugs, 114–116, 345, 346, 347, 498, 927–929

Iran
- biological warfare agents, 12

Iraq
- Acinetobacter infections, 322, 323, 324–327
- biological warfare agents, 10–11
- C. botulinum research program, 339
- Q fever outbreak, 2005, 53–54, 307
- ricin as biological weapon research, 376

Iraq Survey Group, 11

Iron sequestration, 263

Irritants, local
- plants causing, 451

Ishii, General Shiro, 3–4, 5, 338

Ivins, Dr. Bruce E., 15

J

Japan
- Aum Shinrikyo cult bioterrorism research and attacks, 13, 46–47, 72, 339
- biocrimes, 12
- biological agent research during World War I, 3–4
- bioterrorism attacks, 13
- C. botulinum research program, 338
- development of Burkholderia mallei as potential biowarfare agent, 179
- plague warfare research, 252–254
- severe fevers with thrombocytopenia syndrome virus, 676

Japanese encephalitis virus, 550

JBAIDS, See Joint Biological Agent Identification and Diagnostic Systems

Jellyfish stings, 420, 430, 432, 441

Jewett, Frank B., 921

Joint Bacterial Repository, 329

Joint Biological Agent Identification and Diagnostic Systems, 112, 702–704, 738

Joint Biological Integrated Detection System, 112

Joint Task Force for Civil Support, 123

Junin virus, 519–520, 522, 523, 526–528, 530531

Justinian plague, 250

K

Kathmandu, Nepal
- cholera outbreak, 468

Kefauver-Harris Drug Amendments, 926

Kennedy, John F., 7

Khrushchev, Nikita, 9

Killed whole cell vaccines, 206–207

Kosovo
tuberculosis outbreak, 1999–2000, 52–53

Kostov, Vladimir, 9, 376

Krishnaswami, Dr. C.S., 224

L

Laboratories
- allies’ identification levels, 718–719
- antibiotic and antimicrobial susceptibility testing, 727
- assessing individual risk, 876–877
- automated identification systems, 724–727
- Biological Defense Research Program Laboratories, 888
- biosafety program element requirements, 876–886
- biosurveillance, 739–741
- civilian identification levels, 707–708
- Clinical Laboratory Improvement Amendments, 702–703
- Clinical Laboratory Improvement Program, 702–703
- containment and maximum containment laboratories, 876–886
- culture-based microbiological methods, 722–724
- Defense Laboratory Network, 708–707
- documenting safety procedures, 876
- early recognition of host response, 741–743
- electrochemiluminescence, 730–732
- emerging threat surveillance, 739–741
- enzyme-linked immunosorbent assays, 730
- flow cytometry, 732–733
- future perspectives, 734–736
- hand held assays, 733–734
- horizon-agnostic diagnostic applications, 738–739
- identification approaches, 719–739
- identification levels, 707
- immunodiagnostic methods, 728–730
- integration of in vivo and in vitro diagnostic tests, 728
- Joint Biological Agent Identification and Diagnostic Systems, 112, 702, 704
- laboratory animal care and use program, 888–889
- laboratory worker protection, 876
- MAGPIX, 733
- medical surveillance, 880–881
- microbiological culture methods, 727–728
- microbiological practices, 884–886
- military field laboratories, 705–706
- military identification levels, 718, 716–718
- molecular detection methods, 736
- Next Generation Diagnostic System, 702
- next generation molecular diagnostics, 738
- personal protective equipment, 878–880
- physical barriers, 877–878
- presumptive and confirmation methods, 709–716
- protecting the community and environment, 881–882
- rapid methods, 727–728
- real-time polymerase chain reaction, 736–738
- regulated biological select agents and toxins, 703
- research, development, test, and evaluation laboratories, 888
- role of military clinical and field laboratories, 705
- safety audits, 887–888
- solid and liquid waste inactivation and disposal, 882–884
- specimen collection and processing, 719–722
Laboratory-acquired diseases
- botulinum intoxication, 342
- tularemia, 289, 296

Laboratory of HealthCare Associated Infections, 327
Laboratory Registration and Select Agent Transfer Program, 897
Laboratory Response Network, 14, 22, 101, 122, 386, 704, 727–728
Lahore Polo Club, 204

Lambert-Eaton syndrome
differentiating from botulism, 343

Landstuhl Regional Medical Center

Acinetobacter infections, 323, 324–327

Lassa virus, 519, 522, 523–525, 528–531

Latin America
cholera outbreak, 647

LcrV, 261–262
Lectin B-chain, 377–378, 389–390
Legionella, 73–74
Legionellosis, 73–74
Liston, W.G., 256

Live attenuated vaccines, 207, 273, 758, 825–826

Live vaccines
alphavirus encephalitides, 498–499
tularemia, 289, 290, 295–296, 761–763

Livestock. See Animal diseases
Lluvirus, 571–575, 580
Local response, 98–102
London, England
- ricin bioterrorism attack, 16
Louisiana
- plague pandemic, 251
LRN. See Laboratory Response Network
Lujo virus, 519–520, 523
LV5 tularemia vaccine, 295–296

Lyme disease, 652–654
Lymphocyte function-associated antigen, 406
Lysoosomal-related membrane proteins, 308

M-44 vaccine, 312
Machupo virus, 520, 522, 523–524, 526–527, 531
MAGPIX, 733
Major histocompatibility complex, 404–405

Malaysia
Nipah virus outbreak, 553
paramyxovirus infections, 669–670

Malleomyces mallei, 178
Mammarenaviruses. See Hemorrhagic fever-causing mammarenaviruses
Manganese sequestration, 263
MAP. See Mitogen-activated protein kinase
Marburg virus, 571–575, 580–592, 596–598

Marine algal toxins
- amnesic shellfish poisoning, 467–469
- neurotoxic shellfish poisoning, 465–467
- paralytic shellfish poisoning, 463–465

Marine envenoming, 420–422
Markov, Georgi, 9, 375, 376, 382
Marshall, Lieutenant Colonel John D., 252
Marshall Plan, 7
Martha’s Vineyard, Massachusetts
tularemia outbreak, 2000, 51–52, 292
Maryland
alphavirus encephalitides outbreaks, 482
MASCAL. See Medical mass casualty event
Masks, 112–113
Mass median aerodynamic diameter, 862
Mass spectrometry, 202, 328, 344, 386, 387
Massachusetts
- alphavirus encephalitides outbreaks, 482
tularemia outbreak, 2000, 51–52, 292
Mau-Mau attack, 79
MDCK cells, 366
MDR Organism Repository and Surveillance Network, 329–332
MDROs. See Multidrug-resistant organisms
Meadow saffron, 447
MEDCOM. See U.S. Army Medical Command
Medical countermeasures
- anthrax, 752, 754, 757–761
- bacterial diseases, 752–772
botulinum neurotoxin, 793–795
brucellosis, 768–770
encephalitic New World alphaviruses, 773–776
glanders, 766–768
meliodosis, 766–768
plague, 764–765
Q fever, 770–772
ricin, 796–797
rickettsial diseases, 752–772
smallpox, 776–788
Staphylococcal enterotoxin B, 795–796
toxins, 793–797
tularemia, 761–764
viral diseases, 773–793
viral hemorrhagic fevers, 788–793

Medical ethics. See Ethical issues
Medical mass casualty event
casualty management, 110–124
Medical Reengineering Initiative, 705
Medical treatment facilities, 705
Melioidosis
candidate virulence factors, 228–230
clinical disease, 227, 230–232
diagnosis of, 232–233
epidemiology of, 226
infectious agent characteristics, 224–225
medical countermeasures, 766–768
military relevance, 225–226
pathogenesis, 226–227
postexposure prophylaxis, 235–236, 767–768
prevention of, 234–236
treatment of, 233–234
vaccines, 766

Meningitis
- anthrax meningitis, 137
- plague meningitis, 268
Merck, George W., 5
Merck, George W., Jr., 921
Medical Aspects of Biological Warfare

Meropenem
  - glands treatment, 204
  - melioidosis treatment, 233
MERS. See Middle Eastern respiratory syndrome
Meselson, Matthew, 9
Metropolitan Medical Response System, 121
Mexico
  - alphavirus encephalitides outbreaks, 487
Meyer, Karl F., 273
MERS. See Middle Eastern respiratory syndrome
Meselson, Matthew, 9
Metropolitan Medical Response System, 121
Mexico
  - alphavirus encephalitides outbreaks, 487
Meyer, Karl F., 273
MHS. See Military Health System
Mice
  - as animal disease models, 186–188
Microbiological methods
  - culture-based, 722–724, 727–728
Microbiological practices
  - biosafety, 884–886
MicroChem Plus, 883
Middle Eastern respiratory syndrome, 666–669
MIDI Sherlock Microbial Identification System, 199
Military field laboratories, 705–706
Military Health System
  - response to Acinetobacter infections, 328–332
  - military installations. See also U.S. military
    - plague risks, 252, 253
Military personnel
  - options for fulfilling mission and ethical responsibilities, 929–931
Minor Groove Binding Proteins, 630
Missoula, Montana
  - Q fever outbreak, 306
Missouri
  - Heartland virus, 676–677
  - mitogen-activated protein kinase, 134, 378
MNGCs. See Multinucleated giant cells
Modified Vaccinia Ankara, 632
Modified vaccinia virus, 826
Mold toxins, 443
Molecular detection methods
  - Acinetobacter baumannii, 327–328
  - next generation diagnostics, 738
    - overview, 736
Molecular sequencing technology, 58–59
Monkeypox, 623, 627–628
Monoclonal antibodies
  - antibacterial, 837–839
  - antitoxin, 835–837
  - antiviral, 839–842
Monocyte chemoattractant protein-1, 205, 406
Montana
  - Q fever outbreak, 306
Morbidity and Mortality Weekly Report, 259
Mosquitoborne viruses, 670–674
Mousepox virus, 19
MRSN. See MDR Organism Repository and Surveillance Network
Mucosal vaccines, 830–831
Multidrug-resistant organisms
  - antibiotic resistance, 328, 655–656
    - characterization and identification of source, 327–328
    - epidemiological consultation, 324–327
  - ESKAPE pathogens, 322, 328–332
    - genetic analysis, 327–328
  - strain collection and sampling, 327
  - U.S. Military Health System response, 328–332
Multilocus sequence typing, 181, 182
Multinucleated giant cells, 186, 190
Multiple-locus variable number tandem repeat analysis, 182–183
Mushrooms, 422, 442, 444–445, 452
Mussoini, Benito, 375
Myasthenia gravis
  - differentiating from botulism, 343
Myotoxins, 432–435
N
  - National Academy of Sciences, 73, 857
  - National Biosurveillance Integration System, 101
  - National Committee for Clinical Laboratory Standards, 166
  - National Disaster Medical System, 123
  - National Disaster Recovery Framework, 94, 96, 104
  - National Guard, 100, 123
  - National Incident Management System, 96–97, 121
  - National Institute of Occupational Safety and Health, 879
  - National Institutes of Health
    - human genome project, 58
    - Office of Biotechnology Activities, 898
    - Office of Science Policy, 20
  - National laboratories, 122
    - anthrax attack, 2001, 47–48
  - National Disaster Recovery Framework
  - NDRF. See National Disaster Recovery Framework
  - Necrotizing enteritis, 363
  - Nectrotoxins, 442–443
  - Nepal
    - cholera outbreak, 648
    - Nephrotoxic plants, 450
    - Nephrotoxins, 442
    - Nerve agent poisoning
      - differentiating from botulism, 343
      - Neuraminidases, 365, 367
      - Neurotoxic plants, 450
      - Neurotoxin shellfish poisoning
        - description of toxin, 465–466
        - diagnosis of, 467
      - inhalation-acquired disease, 466
      - medical management, 467
      - oral ingestion, 466
  - signs and symptoms, 466
  - Neurotoxins, 340–341, 424–432
  - New Orleans, Louisiana
    - plague pandemic, 251
  - New World mammarenaviruses, 520–521, 523, 526–527, 528–529
  - New York, New York
    - plague pandemic, 251
  - West Nile virus outbreak, 1999, 50–51
  - Next Generation Diagnostic System, 702, 704
    - Next generation molecular diagnostics, 738
    - Next-generation sequencing, 539, 738–739
    - NGDS. See Next Generation Diagnostic System
    - Nightshade, 449
NIH. See National Institutes of Health
Nine Mile variant, 307–308
Nipah virus, 549–552, 553–554, 669–670
Nixon, Richard M., 7, 338, 897
Nomenspecies, 160–161
North America
alphavirus encephalitides outbreaks, 482, 487
North Atlantic Treaty Organization, 718–719
North Carolina
alphavirus encephalitides outbreaks, 482
North Carolina Disease Event Tracking and Epidemiologic Collection Tool, 57
North Korea
accusations of US biowarfare attacks, 6
biological warfare agents, 12
Ninety-Lugar Biological Threat Reduction Program, 10
Nuremberg Code, 921, 922
Nuttall, George, 362
Obama, Barack, 48, 377, 898
Occupational Safety and Health Administration
Respiratory Protection Standard, 879
Osler, William, 291
Office International des Epizooties, 180–181
Office of Biotechnology Activities, 898
Office of Emergency Preparedness, 22
Office of Public Health Emergency Preparedness, 22
Office of Science and Technology Programs, 21
Office of Science Policy, 20
Ofloxacin
glanders, 203
P38 mitogen activated protein kinase, 391
Pacific Yew tree, 449
Paclitaxel, 416–417
Pakistan
glanders outbreak, 204
Palytoxin
dermal exposure, 471
description of toxin, 469–470
diagnosis of, 472
exposure through home aquaria, 471–472
inhalation-acquired disease, 471
mechanism of action, 470
medical management, 472
oral ingestion, 470–471
signs and symptoms, 470–472
Pan-hazard preparedness, 17–24
Pandemics
Avian influenza threat, 657–660
Paralytic neurotoxins, 424–430
Paralytic shellfish poisoning
cause of death, 464
description of toxin, 463
diagnosis of, 465
differentiating from botulism, 343
inhalation-acquired disease, 464
mechanism of action, 463–464
medical management, 465
oral ingestion, 464
signs and symptoms, 464
Paramyxoviruses, 669–670
Parasites, 76–77
Passive antibody therapy
hemorrhagic fever-causing mammarenaviruses, 530
Passive immunotherapy
alphavirus encephalitides, 497–498
bacterial diseases, 758–759
botulinum toxins, 794
henipaviruses, 559–560
Staphylococcal enterotoxin B, 795–796
viral hemorrhagic fevers, 792
PBT. See Pentavalent botulinum toxoid
PCR. See Polymerase chain reaction assays
Peake, Lieutenant General James B., 324
Penicillin
anthrax exposure prophylaxis, 140
anthrax treatment, 139
Pennsylvania
Legionnaires’ disease outbreak, 649
Pensacola, Florida
plague pandemic, 251
Pentavalent botulinum toxoid, 347, 793
Personal protective equipment, 860–861, 877–880
Personnel reliability programs, 898, 901, 905–908

morphology, 617–618
nucleic acid diagnosis, 629–630
pathogenesis, 621–622
phenotypic diagnosis, 628–629
phylogenetic relationships, 620–621
prophylaxis, 630–634
replication, 619
specimen collection and handling, 628
treatment of, 624–635
Outbreak investigations, 41–43

P
p38 mitogen activated protein kinase, 391
Pacific Yew tree, 449
Paclitaxel, 416–417
Pentavalent botulinum toxoid, 261
PCR. See Polymerase chain reaction assays
Peake, Lieutenant General James B., 324
Penicillin
anthrax exposure prophylaxis, 140
anthrax treatment, 139
Pennsylvania
Legionnaires’ disease outbreak, 649
Pensacola, Florida
plague pandemic, 251
Pentavalent botulinum toxoid, 347, 793
Personal protective equipment, 860–861, 877–880
Personnel reliability programs, 898, 901, 905–908

O
Obama, Barack, 48, 377, 898
Occupational Safety and Health Administration
Respiratory Protection Standard, 879
Oculoglandular tularemia, 291
Office International des Epizooties, 180–181
Office of Biotechnology Activities, 898
Office of Emergency Preparedness, 22
Office of Public Health Emergency Preparedness, 22
Office of Science and Technology Programs, 21
Office of Science Policy, 20
Ofloxacin
glanders, 203
Q fever treatment, 311
OFPBL agar, 199
Old World mammarenaviruses, 519–520, 522–523, 525–526, 528
Oleander, 440
Operation Whitecoat, 6, 858, 923
Operations Desert Shield/Storm
biological agents exposure, 10
immunologic protection, 113
pyridostigmine bromide prophylaxis, 113
Operations Enduring Freedom/Iraqi Freedom
Acinetobacter infections, 322, 323, 324–327
Q fever outbreak, 53–54, 307
Oral ingestion
amnesic shellfish poisoning, 468
neurotoxic shellfish poisoning, 466
palytoxin, 470–471
paralytic shellfish poisoning, 464
ricin, 380–382
Oropharyngeal anthrax, 138
Orthopoxviruses
as biological warfare agents, 622–623
characteristics of, 617–622
classification, 617
clinical aspects of infections, 624–628
diagnosis of, 628–630
entry into cells, 618
immunodiagnosis, 629
medical management, 630–635
monkeypox, 627–628
morphogenesis and egress, 619

Medical Aspects of Biological Warfare

PFGE. See Pulsed field gel electrophoresis
Phage shock protein response, 263
Pharyngeal plaque, 268
Phleboviruses, 675–677
Phospholipases, 135
Physical protection, 112–113
PLA2 toxins, 432–434
Plague
antibiotic treatment, 272
autotransporter proteins, 263
biochemistry of, 255–256
as biological warfare agent, 252–254
Black Death, 250–251
bubonic plague, 265, 267
clinical manifestations, 265–269
cutaneous, 268–269
diagnosis of, 269–271
endemic disease, 251–252
epidemiology of, 256–259
F1 antigen, 262
fimbrae, 262–263
first pandemic, 250
gastrointestinal, 268
growth characteristics, 254–255
historical perspectives, 249–251
incidence of, 259–261
infectious agent characteristics, 254–256
iron sequestration, 263
isolation of patients, 271–272
Justinian plague, 250
laboratory confirmation, 269–271
mammals known to harbor plague in the US, 257
manganese sequestration, 263
medical countermeasures, 764–765
meningitis, 268
morphology, 254
pathogenesis, 264–265
phage shock protein response, 263
pharyngeal, 268
plasminogen activator, 262
pneumonic, 259, 267, 268
postexposure prophylaxis, 273, 765
prevention of, 272–273
second pandemic, 250–251
septicemic, 265–267
signs and symptoms, 269
small RNAs, 263
surface structures, 263
taxonomy, 254
third pandemic, 251
transmission of, 2–3
treatment of, 271–274
twin arginine transport, 263
Type III secretion system, 261–262
virulence and transmission factors in the flea, 264
virulence determinants, 261–264
virulence factors in mammalian hosts, 262–263
warfare and, 251–254
Plague Manual, 269
Plaque Vaccine USP, 273
Plant poisons, 422, 440, 446–452
Plaque reduction neutralization test, 629
Plasminogen activator, 262
pMT, 261
Pneumonic plague, 259, 267, 268
Pneumonic tularemia, 291–292
Point source outbreaks, 40

Poisons
animals, 422
as biological warfare agents, 423
definitions, 417
epidemiology of, 418–423
mushrooms, 422, 444–445
plants, 422, 446–452
research directions, 452–453
Poland
use of biological agents during World War II, 4
Poliovirus type 1, 19
Polymerase chain reaction assays
Acinetobacter infection diagnosis, 328
botulism diagnosis, 344
brucellosis diagnosis, 161, 165
filoviruses diagnosis, 593–595
glanders diagnosis, 200, 202
hemorrhagic fever-causing mammarenaviruses diagnosis, 529–530
orthopoxviruses diagnosis, 629–630
overview, 728–730
real-time polymerase chain reaction, 678, 736–738
ricin diagnosis, 387
Staphylococcal enterotoxin B diagnosis, 408
tularemia diagnosis, 293
viral pathogen diagnosis, 678–679
Polysaccharide-based subunit vaccines, 207–208
Portal Shield, 112
Powered air-purifying respirators, 879
Poxviruses, 617
pFCP, 261
Prairie dogs
plague transmission role, 257, 258
President’s Disaster Relief Fund, 100
Presumptive identification methods, 709–716
Primary atypical pneumonia, 307
Primates, nonhuman
as animal disease models, 188
Project 112, 7
Project BioShield Act, 22–23, 740, 926
Pronase, 367
Protective clothing, 112–113
Protective clothing, 112–113
Protein kinases, 391, 406
Protein subunit vaccines, 207
Protein tyrosine kinases, 406
Proteolysis, 364
Proteus OX-19, 4
Protoxin, 367
PFA. See Pteroic acid
Pteroic acid, 390
Public health preparedness, 102
Public Health Security and Bioterrorism Preparedness and Response Act of 2002, 931
Public Health Service Act, 925, 926
Public Readiness and Emergency Preparedness Act, 925
Puffer fish, 422
Pulmonary disease, 365
Pulsed field gel electrophoresis, 325, 327, 328
Purple foxglove, 447
Putin, Vladimir, 10
Pyridostigmine bromide, 113

Q

Q fever
diagnosis of, 311
disease in animals, 310
disease in humans, 310
epidemiology of, 309–310
Gulf War, 307
historical perspectives, 306
infectious agent, 307–309
Iraq outbreak, 2005, 53–54, 307
medical countermeasures, 770–772
military relevance, 306–307
outbreaks during World War II, 8, 306–307
pathogenesis, 309
postexposure prophylaxis, 772
treatment of, 311
vaccines, 115, 312, 770–771
Q-Vax, 312
Queensland, Australia
Q fever outbreak, 306
Quorum sensing systems, 191

R
Rajneesh, Bhagwan Shree, 13, 44–46
Rajneeshee cult
bioterrorism attacks, 13, 44–46
Raman spectroscopy, 202
RANTES protein, 206
Rat fleas
as plague vector, 256
Rats
plague transmission role, 257, 258
Ravn virus, 571–575
Raxibacumab
anthrax treatment, 140
Reagan, Ronald, 9
Real-time Outbreak and Disease Surveillance Laboratory, 57
Real-time polymerase chain reaction, 678, 736–738
Recombinant granulocyte-colony-stimulating factor, 234
Recombinant vaccine vectors, 826–827
Recovery operations, 103–105
Red tides, 466
Reference laboratories, 122
Registered Biosafety Professional, 889–890
Research, development, test, and evaluation laboratories, 888
Research ethics. See Ethical issues
Respiratory Protection Standard, 879
Respiratory system
Staphylococcal enterotoxin B effects, 407
Respiratory tularemia, 291
Reston virus, 571–575, 580, 587
Restriction fragment-length polymorphism, 629–630
RevCons, 17
Reverse transcription-polymerase chain reaction, 558, 678
Review conferences, 17
Rhodesia
biological warfare agents, 11–12
Ribavirin
henipavirus treatment, 560
viral hemorrhagic fever treatment, 790–791
Ribosome inactivating proteins, 377
Richardson, Shannon Guess, 16, 48, 377
Ricin
activity assay, 386
antibody treatment, 388
biochemical identification, 377–378
as biological warfare agent, 376
bioterrorism attacks, 13, 15–16, 376–377
cause of death, 384–385
cellular stress response inhibitors, 391
description of agent, 377–379
detection of, 385–386
diagnosis of, 386–387
enzyme-linked immunosorbent assays, 385, 387
handheld assay detection devices, 365, 387
historical perspectives, 375–376
inhalation of, 382–384
injection of, 382
liquid chromatography/mass spectrometry, 386, 387
medical countermeasures, 796–797
medical management, 387–391
oral intoxication, 380–382
pathogenesis, 378–379
pathology, 379–385
ricin A chain inhibitors, 390–391
sample verification platforms, 385–386
signs and symptoms of, 379–385
small molecule inhibitors, 389–390
Soviet Union attacks, 9
supportive and specific therapy, 389
transport inhibitors, 391
vaccines, 387–388, 796
Rifampin
brucellosis treatment, 167
Riluzole, 366
Ring vaccination, 115
RIPS. See Ribosome inactivating proteins
Risk assessment systems, 95
Risk communication, 115, 124
RiVax, 388
Rock squirrels
plague transmission role, 257, 258
Roosevelt, Franklin D., 5, 858
RTA. See Catalytic A-chain
RTB. See Lectin B-chain
Russell, Findlay E., 416
RVEc, 388

S
Sabiá virus, 521, 523–524, 531
Sarcoiditis
brucellosis and, 164
Safety audits, 887–888
Saint Joseph, Missouri
Heartland virus, 676–677
Salmonella
bioterrorism attacks, 13, 44–46
food- and waterborne, 44–46, 73, 652
Salmonella typhimurium
attacks in Dalles, Oregon, 1984, 44–46
food and waterborne, 73
Salmonellosis
attacks in Dalles, Oregon, 1984, 44–46
food and waterborne, 73
Sample verification platforms, 385–386
San Francisco, California
plague pandemic, 251
Sarin
bioterrorism attacks, 13
SARS, 666
Saudi Arabia
Middle Eastern respiratory syndrome, 666–669
Saxitoxins, 463–465
Scolopendrid centipede, 443
Scorpion stings, 419–420, 430–432, 442–443
Sea snakes, 420–422
Secreted proteins, 189–190
Secretory systems, 189–190
Medical Aspects of Biological Warfare

Security risk assessment, 900
Select Agent List, 22
Select Agent Program, 14, 23
Select Agent Regulations, 900, 902
Select Agent Program, 14, 23
Select Agent Regulations, 900, 902
Senate Office Building
anthrax attack, 2001, 47–48
ricin attacks in 2004, 48–49, 377
Sentinel laboratories, 122
Septic abortions
brucella
and, 162–163
Septicemic disease
plague, 265–267
septicemic glanders, 195
tularemia, 292
Sequence types, 328
Sequencing technology, 58–59
Serologic diagnoses
filoviruses, 583
glanders, 201–202
plague, 270
septicaemia, 293
Severe acute respiratory syndrome, 666
Severe fever with thrombocytopenia syndrome virus, 675–676
Shiga toxins, 74, 377, 651–652
Shigella dysenteriae
attacks in Dallas, Texas, 1996, 47
food and waterborne, 74–75
Shigella sonnei, 78
Shigellosis
attacks in Dallas, Texas, 1996, 47
food and waterborne, 74–75
Shipping standards, 723
Sialidases, 365
Simonson, Stewart, 340
Singapore Armed Forces
melioidosis cases, 225
Skin diseases
cutaneous anthrax, 135–136
cutaneous plague, 268–269
Skin irritation
plants causing, 451
Small molecule inhibitors, 389–390
Small RNAs, 263
Smallpox
as biological warfare agents, 622–623
biothreat policy, 634
cardiovascular symptoms, 617–622
classification, 617
clinical aspects of infections, 624–626
diagnosis of, 628–630
entry into cells, 618
immunodiagnosis, 629
impact on Native Americans, 3
medical countermeasures, 776–788
medical management, 630–635
morphogenesis and egress, 619
morphology, 617–618
nucleic acid diagnosis, 629–630
outbreak in Yugoslavia, 39
pathogenesis, 621–622
phytopathogenic diagnosis, 628–629
phylogenetic relationships, 620–621
preparedness, 18–19
prophylaxis, 630–634
replication, 619
Soviet Union production of virus, 9
specimen collection and handling, 628
treatment of, 624–635
vaccine, 114–115, 777–787
WHO eradication program, 9
Smallpox Response Plan, 628
Smuggling risks, 80
Snakes, venemous, 418–419, 424–426, 428–430, 432–442
Soman
pyridostigmine bromide prophylaxis, 113
South Africa
biological warfare agents, 11–12
South America
alphavirus encephalitides outbreaks, 482
Chikungunya outbreak, 674
South Korea
severe fever with thrombocytopenia syndrome virus, 676
Soviet Union
accidental anthrax release, 49–50, 130
accusations of bioarms attacks, 6–7
biological warfare agents, 8–10
C. botulinum research program, 338–339
filoviruses biological warfare program, 584–586
plague warfare research, 254
ricin as biological weapon research, 376
Specimen collection, 719–722
Spider bites, 419–420, 421, 430, 432, 442–443
Spokane, Washington
ricin attacks in 2004, 377
Squirrels
plague transmission role, 257–258
Stafford Act, 98, 100
Stalin, Joseph, 9
Standing operating procedures, 876
Staphylococcal enterotoxin B
animal models, 405–406
cardiovascular symptoms, 407–408
characterization of, 404–405
clinical disease, 406–408
detection of, 408
development of therapeutics, 409
diagnosis of, 408
fever onset and duration, 407
headache onset and duration, 407
hematology, 408
host response, 405–406
medical countermeasures, 795–796
medical management, 408–409
nausea and vomiting, 407
ocular effects, 408
respiratory symptoms, 407
signs and symptoms, 408–408
vaccines, 409, 795
Staphylococcus aureus
animal models, 405–406
cardiovascular symptoms, 407–408
characterization of toxins, 404–405
clinical disease, 406–408
detection of, 408
development of therapeutics, 409
diagnosis of, 408
fever onset and duration, 409
headache onset and duration, 407
hematology, 408
host response, 405–406
medical countermeasures, 795–796
medical management, 408–409
nausea and vomiting, 407
ocular effects, 408
respiratory symptoms, 407
signs and symptoms, 406–408
vaccines, 409

xlv
State response planning, 102
Sternberg, Surgeon General George, 918
Stillmark, Peter Hermann, 375
Stimson, Henry L., 921
Stingrays, 421–422
Stings, venomous, 418
Strategic National Stockpile, 22–23, 102, 123, 631–632
Streptococcus pyogenes
animal models, 405–406
cardiovascular symptoms, 407–408
characterization of toxins, 404–405
clinical disease, 406–408
detection of, 408
development of therapeutics, 409
diagnosis of, 408
fever onset and duration, 409
headache onset and duration, 407
hematology, 408
host response, 405–406
medical management, 408–409
nausea and vomiting, 407
ocular effects, 408
respiratory symptoms, 407
signs and symptoms, 406–408
vaccines, 409
Streptomycin
brucellosis treatment, 166–167
Glanders treatment, 204
Stroke
differentiating from botulism, 343
Structural vaccinology, 829
Subunit vaccines, 827–829
Sudan virus, 571–575, 587–589, 597
Sulfadiazine
glanders treatment, 204
Superantigens, 404
Supportive therapy
ricin, 389
Staphylococcal enterotoxin B, 408
Surface polysaccharides, 189
Surface structures, 263
Suzuki, Dr. Mitsuru, 12
Sverdlovak, Soviet Union
accidental anthrax release, 49–50, 130
Swine influenza, 660–661
Syndromic surveillance, 56–57
Synthetic biology, 681
Syria
biological warfare agents, 12
ricin as biological weapon research, 376
Systems vaccinology, 829

T

T-cell receptors, 404–405
T-cells
response to Brucella, 163
Tactical Combat Casualty Care, 140
Taenia solium, 76–77
Taq virus, 571–575, 580, 587, 589
Tanzania
Chikungunya outbreak, 673–674
Tapeworms, 76–77
Technical Escort Units, 117
Terrorism, biological. See Bioterrorism
Tetrodotoxin, 422, 426, 430
Texas
plague pandemic, 251
Thailand
botulinum toxin foodborne outbreak, 339–340
meliodosis incidence, 227
Thompson, Diane, 12
Thrombocytopenia syndrome, 675–676
Tickborne disease
anaplasmosis, 654–655
borreliosis, 652–654
differentiating from botulism, 343
Ehrlichiosis, 654–655
Heartland virus, 676–677
paralysis caused by Ixodidae family, 419–420
phleboviruses, 675–677
severe fever with thrombocytopenia syndrome virus, 675–676
TMP-SMX
meliodosis treatment and prophylaxis, 234, 236
Tokyo, Japan
Aum Shinrikyo cult anthrax attacks, 13, 46–47
Toll-like receptors, 404
Toxins
arachnids, 419–420
biological surety, 896–911
as biological warfare agents, 423
bites, 418
botulinum toxins, 72–73, 340–349, 793–795
cardiotoxins, 440–441
classes, 424–425
cnidarians, 420–422
definitions, 417
epidemiology of, 418–423
excitatory neurotoxins, 430–432
fish, 420–422
hemolytic toxins, 437–440
hemorrhagic toxins, 437–440
hemostasis-active toxins, 435–437
insects, 420, 421
marine algal, 462–473
medical countermeasures, 793–797
myotoxins, 432–435
neurotoxins, 442–443
nephrotoxins, 442
origin of word, 2
paralytic neurotoxins, 424–430
research directions, 452–453
scorpions, 419–420
sea snakes, 420–422
snakes, 418–419
spiders, 419–420, 421
staphylococcal enterotoxin B, 404–409, 795–796
stings, 418
Transport inhibitors, 391
Tree squirrels
plague transmission role, 257
Trimethoprim
glanders treatment, 204
Tularemia
aerosol transmission, 288
arthropod vectors, 288
bacterial culture techniques, 293
clinical manifestations, 290–292
diagnosis of, 292–294
direct contact, 287
epidemiology of, 287–289
food and water ingestion, 288
Medical Aspects of Biological Warfare

infectious agent, 286–287
Kosovo outbreak, 1999-2000, 52–53
laboratory-acquired, 289
laboratory worker exposure, 296
mammalian bites, 288
Martha’s Vineyard outbreak, 2000, 51–52, 292
medical countermeasures, 761–764
pathogenesis, 289–290
postexposure prophylaxis, 295, 764
prophylactic treatment, 295–295
rapid diagnostic methods, 293–294
serology, 293
treatment of, 294–295
in unusual settings, 288–289
use as biological weapon, 296
vaccination with live vaccine strain, 289, 290, 295–296, 761–763

U.K. Laboratory of Health Care Associated Infections, 327
Ukraine
plague pandemic, 250, 252
Ulceroglandular tularemia, 291, 292
UN Special Commission, 10, 11
United States Naval Ship Comfort, 323, 325
University of Pittsburgh, 57
UNSCOM. See UN Special Commission
Uruguay Round Agreement on the Application of Sanitary and Phytosanitary Measures, 80
U.S. Army Center for Health Promotion and Preventive Medicine, 324
U.S. Army Medical Command, 329
U.S. Army Medical Research and Materiel Command, 329
U.S. Army Medical Research Institute of Infectious Diseases
anthrax sample testing, 14–15
biosafety, 880–881
casualty management, 110–124
creation of, 8, 923
ricin vaccine research, 388
tularemia vaccine, 295–296
U.S. Congress
anthrax attacks in US, 2001, 47–48, 130
ricin bioterrorism attack, 16, 377
U.S. Department of Agriculture, 5, 23, 44, 80, 101–102, 703, 897
U.S. Department of Defense, 57, 112, 324, 329, 331–332, 628, 704, 888, 927–931
U.S. Department of Energy, 58
U.S. Department of Health and Human Services, 20, 21–22, 100–102, 703, 897
U.S. Department of State, 102
U.S. Department of Transportation, 902
U.S. Environmental Protection Agency, 882–883
U.S. Food and Drug Administration, 82, 112, 272, 587, 702–704, 916, 926–933
U.S. military. See also specific wars by name
biological warfare agents, 4–8
Health System response to Acinetobacter infections laboratories, 705–708, 716–718
options for fulfilling mission and ethical responsibilities to military personnel, 929–931
plague risks at military installations, 252, 253
U.S. National Science Advisory Board for Biosecurity, 59
U.S. Postal Service
anthrax attacks in 2001, 47–48, 130
ricin attacks in 2003-2004, 48–49
ricin bioterrorism attack, 16
USA PATRIOT Act, 897, 900
USAMRIID. See U.S. Army Medical Research Institute of Infectious Diseases
USDA. See U.S. Department of Agriculture

V

V526 vaccine, 500
Vaccine Adverse Event Reporting System, 757
Vaccines
ACAM2000 vaccine, 115
adjuvants, 831–832
adverse events, 757–758
anthrax, 10, 113, 114, 140–141, 753–758
bacterial diseases, 753–756
botulinum toxin, 348, 793–794
brucellosis, 768
Clostridium perfringens, 363, 366–367
filoviruses, 587, 588–589
glanders, 206, 207–208, 766
inactivated, 499
live attenuated vaccines, 207, 273, 758, 825–826
live vaccine strains, 289, 290, 295–296, 498–499
meliodosis, 234–236, 766
mucosal vaccines, 830–831
nucleic acid vaccines, 829–830
orthopoxviruses, 630–634
plague, 115, 273–274, 764–765
Q fever, 115, 312, 770–771
recombinant vaccine vectors, 826–827
ricin, 387–388, 796
rickettsial diseases, 753–754
ring vaccination, 115
smallpox, 114–115, 777–787
Staphylococcal enterotoxin B, 409, 795
Staphylococcus aureus, 409
Streptococcus pyogenes, 409
subunit vaccines, 827–829
trends in biodefense development, 824–825
tularemia, 289, 290, 295–296, 761–763
viral hemorrhagic fevers, 788–790
whole cell vaccines, 312
yellow fever, 115
Vaccinia immune globulin, 633, 634
Vaccinia virus, 825–826
Variola virus, 617, 622–623–626
Vascular leak syndrome, 376
Venezuelan equine encephalitis, 483–484, 485, 492–493, 773–774
Venezuelan hemorrhagic fever, 521, 530
Venoms
arachnids, 419–420
as biological warfare agents, 423
bites, 418
cnidarians, 420–422
definitions, 417
epidemiology of, 418–423
fish, 420–422
insects, 420, 421
research directions, 452–453
scorpions, 419–420
sea snakes, 420–422
snakes, 418–419
spiders, 419–420, 421
stings, 418
Verotoxin, 377
VHF. See Viral hemorrhagic fevers
*Vibrio* cholerae, 77, 647–649
Vibrioses, 649
Vietnam War
meliodosis cases, 225
plague incidence, 252
plague prevention, 249
Viral hemorrhagic fevers, 725, 788–793
Virginia
alphavirus encephalitides outbreaks, 482
Virtual screening, 390, 391
Virulence factors
glanders, 191
meliodosis, 228–230
Virus-like particles, 828
Virus replicon particle vaccines, 501, 827
Virus-Toxin Law, 926

W
W bombs, 376
Walter Reed Army Institute of Research, 324, 327, 328–330
Walter Reed Army Medical Center
*Acinetobacter* infections, 323, 324–327
War Bureau of Consultants, 857
War Research Service, 921
War Reserve Service, 5
Washington
plague pandemic, 251
ricin attacks in 2004, 377
Washington, George, 918
Waste disposal, 882–884
Water Sentinel program, 78
Water supply
bioterrorism concerns, 77–78
security of, 80–82
Waterborne diseases
cholera, 647–649
cryptosporidiosis, 75
emerging diseases, 647–650
*Escherichia coli*, 74
hepatitis A, 75
Legionellosis, 649–650
listeriosis, 73–74
parasites, 76–77
salmonellosis, 73
shigellosis, 74–75
threat potential, 76, 77
vibrioses, 649
Weapons of Mass Destruction-Civil Support Teams, 123
Weekly Epidemiological Record, 259
Welch, William, 362
West Africa
Ebola virus epidemic, 677–678
West Nile virus
New York City outbreak, 1999, 50–51
yearly spread of activity across the U.S., 1999–2004, 672–673
Western blot assay, 202
Western equine encephalitis, 484, 485–486, 494–495, 774–776
Whitmore, Captain Alfred, 224
WHO. See World Health Organization
Whole cell vaccines, 312
Whole genome sequencing, 656–657
Wicker, Roger
ricin attacks in 2004, 48–49, 377
Wood rats
plague transmission role, 258
Working Group on Civilian Biodefense, 272, 273
World Health Assembly, 18
World Health Organization
anthrax surveillance and control guidelines, 140
attempted investigation of biologic agent use during World War II, 6
Plague Manual, 269
smallpox eradication program, 9
Weekly Epidemiological Record, 259
World Trade Organization, 80
World War I and II
gas gangrene, 363
plague attacks, 252–254
plague outbreak, 252
Q fever outbreaks, 8, 306–307
ricin as biological weapon research, 376
use of biological agents, 3–4, 43–44, 78
Wound botulism, 342, 344
WRAIR. See Walter Reed Army Institute of Research

X
Xoma 3AB, 346

Y
Yellow fever, 115
Yellow Fever Commission, 918
Yellow fever virus, 827
Yellow oleander, 440
Yeltsin, Boris, 10, 338–339
*Yersinia pestis*
antibiotic treatment, 272
autotransporter proteins, 263
biochemistry of, 255–256
as biological warfare agent, 252–254
Black Death, 250–251
bubonic plague, 265, 267
characteristics of, 254–256
clinical manifestations, 265–269
cutaneous plague, 268–269
diagnosis of, 269–271
differentiation from *Y. pseudotuberculosis*, 254
endemic disease, 251–252
epidemiology of, 256–259
F1 antigen, 262
fimbriae, 262–263
first pandemic, 250
gastrointestinal plague, 268
growth characteristics, 254–255
historical perspectives, 249–251
incidence of, 259–261
iron sequestration, 263
isolation of patients, 271–272
Justinian plague, 250
laboratory confirmation, 269–271
manganese sequestration, 263
medical countermeasures, 764–765
morphology, 254
pathogenesis, 264–265
phage shock protein response, 263
pharyngeal plague, 268
plague meningitis, 268
plasminogen activator, 262
pneumonic plague, 267, 268
postexposure prophylaxis, 273, 765
prevention of, 272–273
second pandemic, 250–251
septicemic plague, 265–267
Medical Aspects of Biological Warfare

signs and symptoms, 269
small RNAs, 263
surface structures, 263
taxonomy, 254
third pandemic, 251
treatment of, 271–274
twin arginine transport, 263
Type III secretion system, 261–262
vaccines, 115, 273–274, 764–765
virulence and transmission factors in the flea, 264
virulence determinants, 261–264
virulence factors in mammalian hosts, 262–263
warfare and, 251–254
Yersinia pseudotuberculosis, 254, 255
YopK, 262
Yugoslavia
    smallpox outbreak, 39

Z

Zmapp, 792
Zoonotic illnesses. See Animal diseases